世卫发布艾滋病治疗新方针

2009年12月01日 09:04:51 　来源：新华网

世卫组织：全球艾滋病发病数呈下降趋势

１２月１日为世界艾滋病日。世界卫生组织１１月３０日发布艾滋病治疗新指导意见，内容包括逐步淘汰常用艾滋病治疗药剂司他夫定以及艾滋病患者应比先前建议时间更早接受抗逆转录病毒治疗等。

　　建议换药

世卫组织建议，各国应逐渐淘汰艾滋病治疗药剂司他夫定，因为这种药会产生某些“长期、不可治愈”的副作用，包括神经疾病、脂肪萎缩等。

司他夫定又名ｄ４Ｔ，是一种核苷类逆转录酶抑制剂，由美国制药商百时美施贵宝公司制成药物“赛瑞特”投入市场。印度制药商西普拉医药公司、奥罗宾多公司和弧布公司也生产一些未注册的司他夫定药物。

世卫组织说，司他夫定药物价格便宜，使用方便，是许多发展中国家治疗艾滋病的第一选择。不过，司他夫定会引发神经疾病，导致手脚麻木、灼痛以及脂肪萎缩，甚至“致残、致畸”。

世卫组织艾滋病防治部门的西沃恩·克劳利博士说，世卫组织２００６年首次建议各国逐渐淘汰司他夫定。眼下全球超过４００万人使用抗逆转录病毒药物，其中约一半药物含司他夫定，较２００６年减少８０％。

世卫组织提供了对人体危害相对更小的艾滋病治疗药物，如齐多夫定和泰诺福韦，认为它们是“同样有效的选择”。

齐多夫定由英国制药商葛兰素－史克公司率先投入市场，其专利２００５年到期。印度奥罗宾多公司和兰巴克西公司等制药商生产一些未注册齐多夫定药物。美国制药商吉利德科技公司制造泰诺福韦药物“Viread”。

WHO's new AIDS treatment guidelines released
December 1, 2009 09:04:51 Source: Xinhua
WHO: Global AIDS incidence decline in

    December 1 World AIDS Day. World Health Organization November 30 release of new guidance for HIV treatment, including the phasing out of AIDS treatment, commonly used pharmaceutical stavudine, as well as AIDS patients should be sooner than previously recommended antiretroviral therapy.

Suggested dressing

    WHO recommends that countries should gradually phase out AIDS treatment, pharmaceutical stavudine, because such drugs would have some "long-term, non-curable," side effects, including neurological diseases, fat atrophy.

    Stavudine, also known as d4T, is a nucleoside reverse transcriptase inhibitor, by the American pharmaceutical company Bristol-Myers Squibb Company made drugs "Race Reiter," the market. Indian pharmaceutical company Cipla pharmaceutical company Aurobindo and arc cloth companies produce some of unregistered drugs stavudine.

    WHO says drug Stavudine inexpensive, easy to use, the treatment of AIDS in many developing countries, the first choice. However, Stavudine lead to neurological diseases, leading to numbness, burning sensation, as well as fat atrophy, or even "disabled, teratogenic."

    WHO's AIDS department, said Dr. Sivo Enke Crowley, WHO recommends that in 2006 the first time, the phasing out of stavudine. Right now the world's more than 4 million people use anti-retroviral drugs, of which about half of the drug-containing stavudine compared with 2006, reduced by 80%.

    WHO provided a relatively less harmful to human AIDS treatment drugs such as zidovudine and tenofovir that they are "equally valid choice."

    Zidovudine from the British drug maker GlaxoSmithKline - GSK has pioneered the market, its patent expired in 2005. India's Aurobindo and ranbaxy other manufacturers produce some of unregistered drug zidovudine. U.S. pharmaceutical company Gilead Sciences Inc. Tenofovir drug manufacture "Viread".